A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With Narcolepsy
This is a study to evaluate the safety and effectiveness of ADX-N05 compared to placebo in the treatment of excessive daytime sleepiness in adults with narcolepsy.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: ADX-N05
- drug: Placebo
Eligibility
Inclusion Criteria:
- Diagnosis of narcolepsy
- Good general health
- Willing and able to comply with the study design and schedule and other requirements
Exclusion Criteria:
- If female, pregnant or lactating
- Customary bedtime later than midnight
- History of significant medical condition, behavioral, or psychiatric disorder
(including suicidal ideation), or surgical history
- Any other clinically relevant medical, behavioral or psychiatric disorder other than
narcolepsy that is associated with excessive sleepiness
- History of significant cardiovascular disease
- Body mass index > 34
- Excessive caffeine use - > 600 mg/day of caffeine or > 6 cups of coffee/day
- History of alcohol or drug abuse within the past 2 years
- Nicotine dependence that has an effect on sleep
Ages Eligible for Study
18 Years - 70 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Paul Stowers
650-721-7551
I'm interested
Our research team includes physicians, residents, medical students, research assistants, and volunteers. Our research topics include medical imaging, device validation, mobile application development, and pharmaceutical trials.
Some of the Neuro-Opthalmic concerns we investigate include Multiple Sclerosis, Optic Neuritis, IIH, and ICP.